Replies to post #251456 on Biotech Values

[oc631]

(EGRX)—For reasons that are unclear to me, more and more biotech companies are failing to file SEC reports on time; here’s the latest instance

EGRX is still diligently [sarcasm] working on restatements for Q1/Q2 2023.